Free Trial
NASDAQ:ATXI

Avenue Therapeutics (ATXI) Stock Price, News & Analysis

Avenue Therapeutics logo
$0.73 -0.01 (-1.34%)
As of 10/17/2025 12:33 PM Eastern

About Avenue Therapeutics Stock (NASDAQ:ATXI)

Advanced

Key Stats

Today's Range
$0.73
$0.73
50-Day Range
$0.50
$0.90
52-Week Range
$0.17
$2.70
Volume
252 shs
Average Volume
141,738 shs
Market Capitalization
$2.32 million
P/E Ratio
0.04
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Avenue Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

ATXI MarketRank™: 

Avenue Therapeutics scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Avenue Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Avenue Therapeutics is 0.04, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 215.17.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Avenue Therapeutics is 0.04, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 64.36.

  • Price to Book Value per Share Ratio

    Avenue Therapeutics has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Avenue Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.23% of the outstanding shares of Avenue Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Avenue Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Avenue Therapeutics has recently decreased by 6.70%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Avenue Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Avenue Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.23% of the outstanding shares of Avenue Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Avenue Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Avenue Therapeutics has recently decreased by 6.70%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Avenue Therapeutics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    2 people have added Avenue Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Avenue Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.80% of the stock of Avenue Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 17.34% of the stock of Avenue Therapeutics is held by institutions.

  • Read more about Avenue Therapeutics' insider trading history.
Receive ATXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ATXI Stock News Headlines

This dark force is about to change everything
An unstoppable force is reshaping America — one so powerful it’s already disrupting how we work, invest, and live. Porter Stansberry calls it The Final Displacement — a rare turning point that’s only happened four times in human history, each one redefining entire eras. His new documentary reveals why this shift could trigger both immense loss and unprecedented opportunity, and what you can do to prepare before it accelerates.tc pixel
See More Headlines

ATXI Stock Analysis - Frequently Asked Questions

Avenue Therapeutics' stock was trading at $2.00 at the beginning of the year. Since then, ATXI shares have decreased by 63.5% and is now trading at $0.7301.

Avenue Therapeutics, Inc. (NASDAQ:ATXI) issued its quarterly earnings results on Friday, August, 9th. The company reported ($6.43) EPS for the quarter, missing analysts' consensus estimates of ($1.05) by $5.38.

Avenue Therapeutics shares reverse split on the morning of Friday, April 26th 2024.The 1-75 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Avenue Therapeutics (ATXI) raised $30 million in an initial public offering (IPO) on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager.

Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avenue Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), GE Aerospace (GE), CrowdStrike (CRWD) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
8/09/2024
Today
10/18/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ATXI
CIK
1644963
Fax
N/A
Employees
4
Year Founded
2015

Profitability

EPS (Trailing Twelve Months)
($0.95)
Trailing P/E Ratio
0.04
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$10.38 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-471.57%
Return on Assets
-296.50%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.70
Quick Ratio
2.70

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.92 per share
Price / Book
0.38

Miscellaneous

Outstanding Shares
3,183,000
Free Float
2,017,000
Market Cap
$2.32 million
Optionable
Not Optionable
Beta
0.04

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:ATXI) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners